Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131720 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL30628883 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL29277815 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL1131717 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL5106131 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL30777230 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL31136363 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL6097487 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL21782566 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL6338202 | 0.89 | IDO1 (0.51) | ANPEPIDO1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759555-B2 | Stereoselective synthesis of vitamin D analogues | LEO PHARMA A/S (DK) | 2014-06-24 | — | — | US | disclosed |
| US-8362287-B2 | Stereoselective synthesis of vitamin D analogues | LEO PHARMA A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-20120271058-A1 | STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES | SABROE THOMAS PETER (DK) | 2012-10-25 | — | — | US | disclosed |
| EP-1735276-B1 | NOVEL METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF VITAMIN D ANALOGUES | LEO PHARMA AS (DK) | 2011-02-16 | — | — | EP | disclosed |
| EP-1730108-B1 | STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES | LEO PHARMA AS (DK) | 2008-03-26 | — | — | EP | disclosed |
| US-20070135395-A1 | Novel method for the preparation of intermediates useful for the synthesis fo vitamin d analogues | LEO PHARMA A/S (DK) | 2007-06-14 | — | — | US | disclosed |
| US-20070027333-A1 | Stereoselective synthesis of vitamin d analogues | LEO PHARMA A/S (DK) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027333-A1 | Stereoselective synthesis of vitamin d analogues | CYP24A1, CYP2R1, VDR | ANPEP 1385/4885IDO1 3945/4885SLC18A3 3845/4885 |
| US-20120271058-A1 | STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES | CYP24A1, CYP2R1, VDR | ANPEP 1385/4885IDO1 3945/4885SLC18A3 3845/4885 |
| US-20070135395-A1 | Novel method for the preparation of intermediates useful for the synthesis fo vitamin d analogues | CYP2R1, CYP24A1, CYP27B1 | ANPEP 2533/4885IDO1 3459/4885SLC18A3 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.